Study of Pemetrexed for Second-Line Pancreas Cancer

Summary

This study is for patients with pancreatic cancer that has grown and/or spread after having previously received the standard chemotherapy drug called gemcitabine. In this study a drug called pemetrexed is being tested. This drug is approved by the FDA for use in lung cancer and mesothelioma. The purpose of this study is to see if pemetrexed keeps pancreas cancer that has grown and/or spread after gemcitabine from growing. Subjects will receive pemetrexed IV once every 21 days until disease progression or unacceptable side effects occur.

Timeline

Start

2007-10

Primary completion

2009-07

Completion

2009-07

Outcome

Outcome not reported

Stopped: “At interim analysis the study did not meet the response criteria to continue”

Drugs

Indications